Navigation Links
ChemGenex Treats First Patient With Ceflatonin

Melbourne-based ChemGenex Pharmaceuticals has treated the first patient in a new phase II/III clinical study designed to evaluate the efficacy of Ceflatonin// (homoharringtonine or HHT) in patients with Chronic Myeloid Leukemia (CML) who have failed or were intolerant to treatment with two or more prior tyrosine kinase inhibitors (TKIs).

The new study is designed to complement the ongoing registration-directed clinical trial in CML patients with the T315I point mutation and will recruit CML patients from chronic, accelerated and blast-phase disease states.

The patient was enrolled into CML-203 at the MD Anderson Cancer Center in Houston, Texas, and ChemGenex is expanding the study to an estimated 15 centers through the United States and Europe.

It is anticipated that 50-75 patients will be enrolled into CML-203, and that initial data from the study will become available in the first half of calendar year 2008. The primary endpoint for the study will be hematologic response rate, and the cytogenetic response rate will be one of the secondary endpoints assessed.

Mr Greg Collier, ChemGenex’s Managing Director and Chief Executive Officer, said, “This is a companion study to our ongoing CML-202 study, which will form the basis of our initial new drug application (NDA). CML-203 should provide the basis for filing a supplementary NDA, thereby expanding the potential market for the drug.”

Source: BioSpectrum
'"/>




Page: 1

Related medicine news :

1. Cyclosporin A Treats Leukemia Complications
2. Weight Reduction Surgery Also Treats Metabolic Syndrome
3. Chennai Hospital Treats Pakistani Blue Baby
4. Cocoa Treats: Chocolates, as a Health Investment? Chew on this!
5. New Gene Therapy Treats Diabetic Neuropathy
6. Actonel Treats Hip Fractures In A Better Way Than Alendronate
7. BBIC – A SOY-based Substance Treats Multiple Sclerosi
8. Cake Walk – Plum Treats Sell Like Hot Cakes During Christma
9. Common BP Drug Treats Muscular Dystrophy
10. Naltrexone also Treats Crohns Disease
11. Drug for Blood Pressure also Treats Lung Cancer
Post Your Comments:
(Date:1/8/2009)...ions offers five action steps to improve response ...-- Despite the recent three-hour cease fires to al...esidents of the Palestinian territory, upwards of ...ter and medical help. U.S.-based international hum...see this arrangement to allow sporadic delivery of...
(Date:1/8/2009)... of cancer cells are keys to the development of a ...e spread of certain types of cancers called carcin...lung, among others. Armed with a new two-year gra...ch, an Illinois-based philanthropic foundation, im... co-workers at the Moores Cancer Center at the Uni...
(Date:1/8/2009)... at his confirmation hearing to be the next Secret...GTON, Jan. 8 Bipartisan... Tom Daschle, nominee for Department of Health and...w BPC founder and friend Senator Bob Dole at his c...d by the Senate Health, Education, Labor, and Pens...
(Date:1/8/2009)...ctor in Decision for Florida Multi-Specialty Group...wire-FirstCall/ -- Allscripts announced today that...i-specialty group practices in the Southeast Unite...M) Electronic Health Record (EHR) to automate and ...entral Florida. , , (Logo: http://www.newsco...
Breaking Medicine News(10 mins):Health News:Temporary Cease Fires Not Enough for Humanitarian Aid Groups Working in Gaza 2Health News:Temporary Cease Fires Not Enough for Humanitarian Aid Groups Working in Gaza 3Health News:Novel prostate cancer vaccine taking aim at cancer cell 'sweet spot' 2Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 2Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 3Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 4Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 2Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 3Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 4
...uire better memories, literacy skills and math ski...y was conducted by// Laurel Trainor, professor of ...University in Hamilton, Ontario and her team. The... aged 4-6. They took a music test after attending ...
... a pack-a-day crisp habit is prevalent among 55% o...alent of five litres of// cooking oil annually. T...g people about the amount of hidden salt, fat and ...were releases as a part of it. 'I am concerned we ...
...d Journal of Medicine says that stem cells may not...h is needed to ascertain// these findings. Three ...o survivors of heart attacks and found that these ...maged hearts. Researchers looked at whether stem c...
...t is considering introducing a needle exchange pro...king can trigger// diseases like Hepatitis C and H...y have shared needles in prison. There will always...in prison," a SPS spokesman told BBC. "If you're n...
Other Medicine News:
(Date:1/6/2009)...In recent controlled studies conducted by Dr. Rich...ound that the patented ingredient in Glyc,n Go(TM)...dient to increase levels of nitric oxide (NO) in t...(NOx) in human subjects. , , Nitric oxide acts ...flow to the skeletal muscles. This is significant...
(Date:1/6/2009)...re-FirstCall/ -- , - Early Renewal of the A...er 2011 , - Expansion of the Scope of the C...thalmology , - Revised Commercial Terms and... Third Party , ExonHit Therapeutics (Alte...its existing drug discovery collaboration with All...
(Date:12/30/2008)...wire/ -- The Coalition for 21st Century Medicine s...ntech, Inc. on December 5, 2008, seeking to restri... tests to physicians and patients. The request th... patient care and rests on flawed scientific and l...o encourage the research, development, and commerc...
(Date:12/17/2008)...nd validation of non-animal alternative test metho... -- MatTek Corporation today announced that the EC...the scientific validity of the Modified EpiDerm Sk... ESAC concluded that the Modified EpiDerm SIT has ...tion of skin irritating and non-irritating test su...
Breaking Medicine Technology:US Testing Proves Glyc'n Go(TM) Increases NO in the Blood Stream 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 3ExonHit Therapeutics Expands Strategic Collaboration With Allergan 4Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 2Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 3Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 4EpiDerm's Skin Irritation Test Fully Validated in European Union 2UNIVAL Inc Becomes a Google Health 28TM 29 Integrated Service 19918 1UNIVAL Inc Becomes a Google Health 28TM 29 Integrated Service 19918 2TV Icon Takes a Shot at Staying Slim 19916 1TV Icon Takes a Shot at Staying Slim 19916 2Annual FIT Testing Detects Colorectal Cancer Two Years Earlier Than Colonoscopy Alone Study of High Risk Population Finds 2142 1Annual FIT Testing Detects Colorectal Cancer Two Years Earlier Than Colonoscopy Alone Study of High Risk Population Finds 2142 2Annual FIT Testing Detects Colorectal Cancer Two Years Earlier Than Colonoscopy Alone Study of High Risk Population Finds 2142 3Annual FIT Testing Detects Colorectal Cancer Two Years Earlier Than Colonoscopy Alone Study of High Risk Population Finds 2142 4Annual FIT Testing Detects Colorectal Cancer Two Years Earlier Than Colonoscopy Alone Study of High Risk Population Finds 2142 5Ohio State University Medical Center to Test Efficacy of Hyperbaric Oxygen Medicine on Stroke Victims 19914 1Ohio State University Medical Center to Test Efficacy of Hyperbaric Oxygen Medicine on Stroke Victims 19914 2
...ry and secondary endpoints of,study; no negative d...tabine and ribavirin ~, CAMBRIDGE, Mass., June 12,...cals, Inc. today announced results from a phase II...rapy, consisting of,valopicitabine (NM283), Idenix...tis C, pegylated interferon and ribavirin,compared...
...RNewswire/ -- Accera, Inc.,today is presenting dat...inical trial of AC-1202 (Ketasyn) in Alzheimer,s d...national Conference on,Prevention of Dementia in W...rlier clinical and preclinical studies, AC-1202 wa...e memory and,cognition of subjects of a particular...
Other Medicine Technology:Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 2Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 3Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 4Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 5Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 6Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia 2Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia 3Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia 4
A rapid rise in intracranial pressure requires early recognition, intervention and continuous monitoring. Ventrix utilizes state-of-the-art fiberoptic technology that gets to the source of pressure.
The MPM-1 offers a broad range of functions to attain new levels of parenchymal and ventricular monitoring through fiberoptic technology at the source.
The Codman ICP Monitoring System provides highly accurate measurements of intracranial pressure at the source-subdural, parenchymal or intraventricular levels. The information is relayed electronical
The Polaris system delivers the most innovative optical tracking technology. Compact, cost effective and easy to use, this unique system combines the highest level of precision measurement with unpre
Medicine Products: